Tested Applications
| Positive WB detected in | Raji cells, mouse spleen tissue, Ramos cells, Daudi cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:16000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
84523-4-RR targets CD79b in WB, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
FusionProtein Predict reactive species |
| Full Name | CD79B antigen |
| Calculated Molecular Weight | 26 kDa |
| Observed Molecular Weight | 36-40 kDa |
| GenBank Accession Number | NM_008339.3 |
| Gene Symbol | Cd79b |
| Gene ID (NCBI) | 15985 |
| RRID | AB_3672031 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purfication |
| UNIPROT ID | P15530 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
CD79 molecule encompasses two transmembrane proteins, CD79a and CD79b, which form a disulfide-linked heterodimer and are members of the immunoglobulin (Ig) gene superfamily (PMID: 2033258; 1375264; 2304550). CD79b molecule (also known as B29, IGB, AGM6, and Igbeta) is expressed almost exclusively on B cells and B-cell neoplasms, influencing antigen internalization and increasing antigen presentation efficiency (PMID: 7552998). CD79b mutation could be a key biomarker for DLBCL disease progression (PMID: 36182550).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for CD79b antibody 84523-4-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
84523-4-RR is a human recombinant anti-SIRT1 antibody with 1 total citation. It appears in Cancer Medicine (Impact Factor 3.5), published in October 2025. The cited study investigated SIRT1 expression in human gastrointestinal tumors and its clinical significance, using the antibody for Western blot analysis. The research field is cancer biology, specifically gastrointestinal oncology.
| Species | Application | Title |
|---|---|---|
Cancer Med SIRT1 Expression in Human Gastrointestinal Tumors and Its Clinical Significance |





